Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2026-09-01 18:20:52 ET · period of report 2026-09-01 · accession 0001875714-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-01 18:20 | 2026-09-01 | XERS | Pieper Steven | See Remarks | S - Sale | $8.50 | -5,000 | 1.36M | -0.4% | -$42.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-01 | S | D | 5,000 | $8.50 | 1,356,053 | D | — | — | (F1) The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. |